Figure 1.

Effects of ES-62 on antigen-specific CD4⁺ T cell and B220⁺ B-cell clonal expansion in vivo. Non-transgenic BALB/c recipient control and ES-62 treated mice were injected with 2·5 × 10⁶ CD4⁺ KJ1.26⁺ T cells (a) or 2·5 × 10⁶ CD4⁺ KJ1.26⁺ T cells and B220⁺ HEL⁺ B cells (b and c). Twenty-four hr later, these mice were immunized s.c with 130 µg OVA–HEL in CFA. The percentage of CD4⁺ KJ1.26⁺ T cells (a and b) and B220⁺ HEL⁺ B cells (c) in the draining lymph nodes of adoptively transferred recipients was assessed by flow cytometry on days 3, 5, 7 and 10 after immunization. Each time point represents the mean ± SEM for three mice per group, **P < 0·01 where U represents unimmunized, control mice; E represents unimmunized, ES-62-treated mice; I represents immunized control mice and I + E represents immunized, ES-62-treated mice. Data are representative of at least four independent experiments and the day 5 T-cell clonal expansion data from four of these experiments have been pooled and presented in (d) **P < 0·01 for I (immunized, control mice) versus I + E (immunized, ES-62-treated mice) from single transfer experiments and *P < 0·05 for immunized, ES-62-treated single transfer versus double transfer mice.